UFP Technologies, Inc.
189.37-8.52 (-4.31%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · UFPT · USD
Key Stats
Market Cap
1.46BP/E (TTM)
21.99Basic EPS (TTM)
8.61Dividend Yield
0%Recent Filings
8-K
UFP updates MedTech growth strategy
UFP Technologies released updated investor presentation materials on August 21, 2025, highlighting its transformation into a MedTech-focused CDMO with pro forma annual revenue of ~$600 million and market cap of ~$1.95 billion. The company targets 12-18% revenue growth over three to five years through organic expansion in high-margin segments like robotic surgery and strategic acquisitions, aiming for 28-31% gross margins and 17-20% adjusted operating margins. MedTech now drives 92% of sales, up from $132 million in 2021. Forward-looking statements carry risks from customer concentration and supply chain disruptions.
10-Q
Q2 FY2025 results
UFP Technologies posted solid Q2 FY2025 results, with net sales climbing 37.2% year-over-year to $151.2M, driven by 46.0% medical market growth including $35.7M from recent acquisitions, while organic sales rose 4.9% (derived). Gross margin dipped to 28.8% from 30.0%, hit by $1.2M in AJR integration inefficiencies, yet operating income surged 35.6% to $24.3M and diluted EPS hit $2.21, up 26.3%, reconciling cleanly with 7,773K shares. Year-to-date, sales jumped 39.1% to $299.3M, EPS $4.42 (up 30.8%), and operating cash flow reached $39.1M, yielding $33.5M free cash flow after $5.7M capex (derived). Debt stood at $163.6M under the $275M facility (5.7% rate, compliant), with $14.9M cash; post-quarter buys of UNIPEC ($7.5M cash, July 2025) and TPI ($4.5M cash, July 2025) bolster medical components. Acquisitions fuel momentum. Customer concentration lingers as a risk.
8-K
Record Q2 sales surge
UFP Technologies posted record Q2 sales of $151.2 million, up 37% from last year, fueled by acquisitions and 5% organic growth, though non-medical sales dipped 20%. MedTech revenue surged 46% to $139.3 million, but gross margins slipped to 28.8% from labor issues at a new facility. Adjusted EPS climbed 27% to $2.50. Acquisitions expand molding capabilities; pipeline remains robust.
8-K
UFP acquires UNIPEC, TPI
UFP Technologies completed acquisitions of UNIPEC and TPI on July 17, 2025, bolstering its medical device capabilities in precision thermoforming and thermoplastic molding. UNIPEC, with $5 million revenue and $2 million EBITDA, was bought for $7.5 million cash at 3.75 times adjusted EBITDA; TPI, generating $10 million revenue and $1 million EBITDA, cost $4.5 million at 4.5 times. These deals expand UFP's thin film and injection molding for implantables and OEMs, financed via cash and credit. Integration risks could hinder expected synergies.
8-K
UFP updates MedTech growth strategy
UFP Technologies released updated investor presentation materials on June 10, 2025, highlighting its shift to high-margin MedTech, now comprising 91% of revenue with pro forma annual sales around $600 million. The company targets 12-18% revenue growth over three to five years through organic expansion in robotic surgery and strategic acquisitions, aiming for 28-31% gross margins and 17-20% adjusted operating margins. Acquisitions since 2021 have boosted MedTech sales from $132 million in 2021 to $451 million in 2024. Forward-looking statements carry risks like customer concentration and supply chain disruptions.
CNMD
CONMED Corporation
46.71-0.61
ENOV
Enovis Corporation
31.99-0.87
MDT
Medtronic plc.
91.73-1.50
MHUA
Meihua International Medical Te
0.23-0.03
NAOV
NanoVibronix, Inc.
5.57-0.32
SNWV
SANUWAVE Health, Inc.
30.44-0.60
STE
STERIS plc (Ireland)
236.79-4.41
UEEC
United Health Products, Inc.
0.07-0.01
UFPI
UFP Industries, Inc.
90.03-1.95
UTMD
Utah Medical Products, Inc.
57.02-1.51